Sanofi has received orphan designation from the EMA for rilzabrutinib, a reversible covalent BTK inhibitor, to treat IgG4-RD.

The US-EU pharma tariff cap has been finalized at 15%, impacting manufacturing, supply chain, and quality and promoting ...